Cargando…

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Coronavirus disease 2019 (COVID-19) is characterized by distinct patterns of disease progression that suggest diverse host immune responses. We performed an integrated immune analysis on a cohort of 50 COVID-19 patients with various disease severity. A distinct phenotype was observed in severe and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Hadjadj, Jérôme, Yatim, Nader, Barnabei, Laura, Corneau, Aurélien, Boussier, Jeremy, Smith, Nikaïa, Péré, Hélène, Charbit, Bruno, Bondet, Vincent, Chenevier-Gobeaux, Camille, Breillat, Paul, Carlier, Nicolas, Gauzit, Rémy, Morbieu, Caroline, Pène, Frédéric, Marin, Nathalie, Roche, Nicolas, Szwebel, Tali-Anne, Merkling, Sarah H., Treluyer, Jean-Marc, Veyer, David, Mouthon, Luc, Blanc, Catherine, Tharaux, Pierre-Louis, Rozenberg, Flore, Fischer, Alain, Duffy, Darragh, Rieux-Laucat, Frédéric, Kernéis, Solen, Terrier, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402632/
https://www.ncbi.nlm.nih.gov/pubmed/32661059
http://dx.doi.org/10.1126/science.abc6027
_version_ 1783566793419259904
author Hadjadj, Jérôme
Yatim, Nader
Barnabei, Laura
Corneau, Aurélien
Boussier, Jeremy
Smith, Nikaïa
Péré, Hélène
Charbit, Bruno
Bondet, Vincent
Chenevier-Gobeaux, Camille
Breillat, Paul
Carlier, Nicolas
Gauzit, Rémy
Morbieu, Caroline
Pène, Frédéric
Marin, Nathalie
Roche, Nicolas
Szwebel, Tali-Anne
Merkling, Sarah H.
Treluyer, Jean-Marc
Veyer, David
Mouthon, Luc
Blanc, Catherine
Tharaux, Pierre-Louis
Rozenberg, Flore
Fischer, Alain
Duffy, Darragh
Rieux-Laucat, Frédéric
Kernéis, Solen
Terrier, Benjamin
author_facet Hadjadj, Jérôme
Yatim, Nader
Barnabei, Laura
Corneau, Aurélien
Boussier, Jeremy
Smith, Nikaïa
Péré, Hélène
Charbit, Bruno
Bondet, Vincent
Chenevier-Gobeaux, Camille
Breillat, Paul
Carlier, Nicolas
Gauzit, Rémy
Morbieu, Caroline
Pène, Frédéric
Marin, Nathalie
Roche, Nicolas
Szwebel, Tali-Anne
Merkling, Sarah H.
Treluyer, Jean-Marc
Veyer, David
Mouthon, Luc
Blanc, Catherine
Tharaux, Pierre-Louis
Rozenberg, Flore
Fischer, Alain
Duffy, Darragh
Rieux-Laucat, Frédéric
Kernéis, Solen
Terrier, Benjamin
author_sort Hadjadj, Jérôme
collection PubMed
description Coronavirus disease 2019 (COVID-19) is characterized by distinct patterns of disease progression that suggest diverse host immune responses. We performed an integrated immune analysis on a cohort of 50 COVID-19 patients with various disease severity. A distinct phenotype was observed in severe and critical patients, consisting of a highly impaired interferon (IFN) type I response (characterized by no IFN-β and low IFN-α production and activity), which was associated with a persistent blood viral load and an exacerbated inflammatory response. Inflammation was partially driven by the transcriptional factor nuclear factor–κB and characterized by increased tumor necrosis factor–α and interleukin-6 production and signaling. These data suggest that type I IFN deficiency in the blood could be a hallmark of severe COVID-19 and provide a rationale for combined therapeutic approaches.
format Online
Article
Text
id pubmed-7402632
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-74026322020-08-19 Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients Hadjadj, Jérôme Yatim, Nader Barnabei, Laura Corneau, Aurélien Boussier, Jeremy Smith, Nikaïa Péré, Hélène Charbit, Bruno Bondet, Vincent Chenevier-Gobeaux, Camille Breillat, Paul Carlier, Nicolas Gauzit, Rémy Morbieu, Caroline Pène, Frédéric Marin, Nathalie Roche, Nicolas Szwebel, Tali-Anne Merkling, Sarah H. Treluyer, Jean-Marc Veyer, David Mouthon, Luc Blanc, Catherine Tharaux, Pierre-Louis Rozenberg, Flore Fischer, Alain Duffy, Darragh Rieux-Laucat, Frédéric Kernéis, Solen Terrier, Benjamin Science Reports Coronavirus disease 2019 (COVID-19) is characterized by distinct patterns of disease progression that suggest diverse host immune responses. We performed an integrated immune analysis on a cohort of 50 COVID-19 patients with various disease severity. A distinct phenotype was observed in severe and critical patients, consisting of a highly impaired interferon (IFN) type I response (characterized by no IFN-β and low IFN-α production and activity), which was associated with a persistent blood viral load and an exacerbated inflammatory response. Inflammation was partially driven by the transcriptional factor nuclear factor–κB and characterized by increased tumor necrosis factor–α and interleukin-6 production and signaling. These data suggest that type I IFN deficiency in the blood could be a hallmark of severe COVID-19 and provide a rationale for combined therapeutic approaches. American Association for the Advancement of Science 2020-08-07 2020-07-13 /pmc/articles/PMC7402632/ /pubmed/32661059 http://dx.doi.org/10.1126/science.abc6027 Text en Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reports
Hadjadj, Jérôme
Yatim, Nader
Barnabei, Laura
Corneau, Aurélien
Boussier, Jeremy
Smith, Nikaïa
Péré, Hélène
Charbit, Bruno
Bondet, Vincent
Chenevier-Gobeaux, Camille
Breillat, Paul
Carlier, Nicolas
Gauzit, Rémy
Morbieu, Caroline
Pène, Frédéric
Marin, Nathalie
Roche, Nicolas
Szwebel, Tali-Anne
Merkling, Sarah H.
Treluyer, Jean-Marc
Veyer, David
Mouthon, Luc
Blanc, Catherine
Tharaux, Pierre-Louis
Rozenberg, Flore
Fischer, Alain
Duffy, Darragh
Rieux-Laucat, Frédéric
Kernéis, Solen
Terrier, Benjamin
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
title Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
title_full Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
title_fullStr Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
title_full_unstemmed Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
title_short Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
title_sort impaired type i interferon activity and inflammatory responses in severe covid-19 patients
topic Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402632/
https://www.ncbi.nlm.nih.gov/pubmed/32661059
http://dx.doi.org/10.1126/science.abc6027
work_keys_str_mv AT hadjadjjerome impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT yatimnader impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT barnabeilaura impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT corneauaurelien impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT boussierjeremy impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT smithnikaia impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT perehelene impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT charbitbruno impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT bondetvincent impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT cheneviergobeauxcamille impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT breillatpaul impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT carliernicolas impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT gauzitremy impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT morbieucaroline impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT penefrederic impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT marinnathalie impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT rochenicolas impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT szwebeltalianne impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT merklingsarahh impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT treluyerjeanmarc impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT veyerdavid impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT mouthonluc impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT blanccatherine impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT tharauxpierrelouis impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT rozenbergflore impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT fischeralain impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT duffydarragh impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT rieuxlaucatfrederic impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT kerneissolen impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients
AT terrierbenjamin impairedtypeiinterferonactivityandinflammatoryresponsesinseverecovid19patients